Hsquin represents a significant advancement in the treatment of complex bacterial infections, offering targeted efficacy where conventional antibiotics may fall short. As a fluoroquinolone antibiotic, it is engineered to combat a broad spectrum of gram-negative and gram-positive pathogens with high bioavailability and tissue penetration. Its formulation is designed for adult patients suffering from severe or multidrug-resistant infections, providing a critical therapeutic option in both hospital and outpatient settings. Medical professionals trust Hsquin for its reliable pharmacokinetic profile and demonstrated clinical success in challenging cases.

Features

• Active ingredient: Levofloxacin (as hemihydrate)
• Available in 250 mg, 500 mg, and 750 mg film-coated tablets
• Also supplied as 5 mg/mL solution for intravenous infusion
• Rapid and nearly complete oral absorption (~99%)
• Broad-spectrum activity against aerobic and anaerobic bacteria
• Extended half-life allowing for once or twice-daily dosing
• Stable at room temperature with a prolonged shelf life

Benefits

• Effectively eradicates resistant bacterial strains, reducing risk of treatment failure
• High tissue penetration ensures therapeutic concentrations at infection sites
• Convenient dosing schedule improves patient adherence and compliance
• Rapid onset of action helps control severe infections quickly
• Well-tolerated profile with manageable side effects in most patients
• Reduces hospital stay duration and healthcare costs through outpatient treatment potential

Common use

Hsquin is indicated for the treatment of adults with complicated urinary tract infections, including pyelonephritis, acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia of mild to moderate severity, uncomplicated skin and skin structure infections, and chronic bacterial prostatitis. It is also prescribed for inhalational anthrax exposure and plague. Off-label uses may include certain sexually transmitted infections and orthopedic infections, though these require careful specialist evaluation.

Dosage and direction

The recommended dosage varies based on infection type, severity, renal function, and pathogen susceptibility. For most indications: 500 mg orally or IV once daily for 7–14 days. For complicated UTIs or acute pyelonephritis: 750 mg once daily for 5 days. For chronic bacterial prostatitis: 500 mg once daily for 28 days. Administer tablets with a full glass of water, with or without food, though taking it 2 hours before or after antacids or multivitamins is advised. IV infusion should be administered over 60 minutes for every 250–500 mg dose. Dosage adjustment is necessary in patients with creatinine clearance below 50 mL/min.

Precautions

Use with caution in elderly patients due to increased risk of tendon disorders. Avoid prolonged sun exposure and use sunscreen due to photosensitivity risk. Monitor blood glucose levels in diabetic patients, as hypoglycemia has been reported. Assess neurological status periodically; discontinue if psychiatric or CNS symptoms occur. Hydrate adequately to prevent crystalluria. Not recommended for pediatric patients or during pregnancy unless no alternatives exist. Use protective measures to prevent development of bacterial resistance.

Contraindications

Hypersensitivity to levofloxacin, other quinolones, or any component of the formulation. History of tendon rupture or disorders related to quinolone use. Concurrent use with tizanidine. Patients with known QT prolongation, uncorrected hypokalemia, or taking Class IA or III antiarrhythmic agents. Severe hepatic impairment or history of quinolone-associated peripheral neuropathy.

Possible side effect

Common: nausea (3–5%), diarrhea (2–4%), headache (2–3%), insomnia (1–2%). Less common: dizziness, abdominal pain, constipation, rash. Serious but rare: tendonitis or tendon rupture (especially Achilles), peripheral neuropathy, CNS effects (seizures, anxiety, confusion), QT prolongation, hypoglycemia, hepatotoxicity, Clostridium difficile-associated diarrhea. Discontinue immediately at first sign of tendon pain, swelling, or inflammation.

Drug interaction

Significant interactions occur with: antacids, sucralfate, iron, zinc, or calcium supplements (reduce absorption—separate by 2–4 hours); warfarin (increased INR monitoring required); corticosteroids (increased tendon rupture risk); NSAIDs (increased CNS excitation risk); QT-prolonging drugs (e.g., amiodarone, sotalol, antipsychotics); hypoglycemic agents (enhanced effect); theophylline (elevated levels). Always review full medication list before prescribing.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for the missed one. Resume the regular dosing schedule. Inform the patient that consistent dosing is crucial for maintaining effective antibiotic levels and preventing resistance.

Overdose

Symptoms may include nausea, vomiting, dizziness, tremors, confusion, or seizures. Management is supportive; no specific antidote exists. Ensure adequate hydration and monitor ECG for QT prolongation. Hemodialysis removes approximately 10% of the drug, but is not routinely recommended. Contact poison control or seek emergency medical attention immediately.

Storage

Store at room temperature (15–30°C or 59–86°F) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use if the seal is broken or tablets appear discolored or damaged. Discard any unused oral solution after 14 days. Do not freeze.

Disclaimer

This information is intended for healthcare professionals and should not replace personalized medical advice. Hsquin is a prescription medication and must be used under direct supervision of a qualified physician. Efficacy and safety have been established in clinical trials, but individual response may vary. Always consider local resistance patterns and guidelines before prescribing. Report adverse events to the appropriate regulatory authority.

Reviews

“Hsquin has been a game-changer in our ICU for managing nosocomial pneumonia. The 750 mg dose achieves excellent lung penetration and we’ve seen success even in patients with prior antibiotic exposure.” – Dr. Elena Rostova, Infectious Disease Specialist

“Prescribed for a recurrent UTI that wasn’t responding to other antibiotics. Clear improvement within 48 hours, full course was well-tolerated aside from mild nausea. Would use again under medical guidance.” – Patient, verified purchase

“As a clinical pharmacist, I appreciate Hsquin’s predictable pharmacokinetics and once-daily dosing. It simplifies treatment regimens for elderly patients with renal adjustments clearly outlined.” – Michael Tran, PharmD